Veracyte

VCYT · NASDAQ

$44.79+$0.99 (+2.26%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $43.80

Latest news

NewsOct 6, 11:46 AM ETChandrima Sanyal
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
NewsSep 22, 10:40 AM ETChandrima Sanyal
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
NewsAug 19, 6:30 AM ETAvi Kapoor
Top 3 Health Care Stocks That Could Blast Off This Month
NewsJul 31, 8:03 AM ETAvi Kapoor
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
Press releaseJul 30, 4:05 PM ETGlobe Newswire
Veracyte Announces Second Quarter 2026 Financial Results
Press releaseJul 9, 4:05 PM ETBusiness Wire
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
NewsJun 10, 10:43 PM ETShivdeep Dhaliwal
Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock
Press releaseJun 1, 7:30 AM ETBusiness Wire
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
Press releaseMay 30, 8:00 AM ETBusiness Wire
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
Press releaseMay 29, 3:15 PM ETBusiness Wire
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
Press releaseMay 22, 8:00 AM ETBusiness Wire
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
Press releaseMay 21, 6:00 PM ETBusiness Wire
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
Press releaseMay 19, 4:05 PM ETBusiness Wire
Veracyte to Participate in Upcoming Investor Conferences
Press releaseMay 15, 9:00 AM ETBusiness Wire
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
Press releaseMay 13, 9:00 AM ETGlobe Newswire
A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
NewsMay 6, 1:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsMay 5, 5:35 PM ET
Full Transcript: Veracyte Q1 2026 Earnings Call
NewsMay 5, 4:07 PM ET
Veracyte Q1 Adj. EPS $0.52 Beats $0.15 Estimate, Sales $139.071M Beat $130.041M Estimate
Press releaseMay 5, 4:05 PM ETBusiness Wire
Veracyte Announces First Quarter 2026 Financial Results
NewsMay 5, 7:12 AM ET
Earnings Scheduled For May 5, 2026
Press releaseApr 28, 9:00 AM ETBusiness Wire
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
Press releaseApr 14, 4:05 PM ETBusiness Wire
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
Press releaseMar 16, 4:15 PM ETBusiness Wire
Veracyte Names Kevin Haas as Chief Development and Technology Officer
NewsFeb 25, 4:16 PM ET
Earnings Breakdown: Veracyte Q4
NewsFeb 25, 4:14 PM ET
Veracyte Q4 Adj. EPS $0.53 Beats $0.36 Estimate, Sales $140.636M Beat $136.944M Estimate
Press releaseFeb 25, 4:05 PM ETBusiness Wire
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
Press releaseFeb 24, 9:00 AM ETBusiness Wire
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
Press releaseFeb 19, 5:00 PM ETBusiness Wire
Veracyte to Participate in Upcoming Investor Conferences
Press releaseFeb 4, 5:15 PM ETBusiness Wire
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
Press releaseJan 11, 4:30 PM ETBusiness Wire
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
Press releaseDec 31, 7:25 AM ETPRNewswire
Smart Oncology: 5 Stocks Chasing the $317B Prize
Press releaseDec 29, 4:30 PM ETBusiness Wire
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Press releaseNov 6, 8:30 AM ETBusiness Wire
Veracyte to Participate in Upcoming Investor Conferences
NewsNov 5, 7:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseNov 4, 4:05 PM ETBusiness Wire
Veracyte Announces Third Quarter 2025 Financial Results
Press releaseNov 3, 4:15 PM ETBusiness Wire
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
Press releaseOct 15, 5:31 PM ETBusiness Wire
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
Press releaseSep 28, 4:00 PM ETBusiness Wire
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
Press releaseSep 4, 4:05 PM ETBusiness Wire
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up

Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets

Top 3 Health Care Stocks That Could Blast Off This Month

Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

Veracyte Announces Second Quarter 2026 Financial Results

Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer

Veracyte to Participate in Upcoming Investor Conferences

Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer

A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

12 Health Care Stocks Moving In Wednesday's Intraday Session

Full Transcript: Veracyte Q1 2026 Earnings Call

Veracyte Q1 Adj. EPS $0.52 Beats $0.15 Estimate, Sales $139.071M Beat $130.041M Estimate

Veracyte Announces First Quarter 2026 Financial Results

Earnings Scheduled For May 5, 2026

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

Veracyte Names Kevin Haas as Chief Development and Technology Officer

Earnings Breakdown: Veracyte Q4

Veracyte Q4 Adj. EPS $0.53 Beats $0.36 Estimate, Sales $140.636M Beat $136.944M Estimate

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

Veracyte to Participate in Upcoming Investor Conferences

Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Smart Oncology: 5 Stocks Chasing the $317B Prize

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Veracyte to Participate in Upcoming Investor Conferences

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Veracyte Announces Third Quarter 2025 Financial Results

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors